Pre-Clinical Trial Using Fresh Tumor Directly From Patients Case Show
LIDE provides in vitro assay using fresh tumor tissues directly from patients. Cancer cells isolated from peripheral blood or bone marrow can be bred with labeled anti-CD47 antibody to see the binding effect, whereas additional Mφ can be applied to evaluate Antibody-Derived Cell Phagocytosis (ADCP). Results of binding (upper right) and phagocytosis (bottom right) were shown, in which each number in X axis represents an independent patient samples, like a clinical trial that enrolling patients one by one. The two tested antibodies exerted good binding effect. However, not all the positive binding can transfer to phagocytosis, which would be the real condition occurred in clinical.